Thermo Fisher closes $13.6B Life Tech acquisition

Thermo Fisher ($TMO) has closed its mammoth $13.6 billion buyout of Life Technologies, barely a few days after U.S. antitrust regulators signed off on the deal. The acquisition breaks down to $76.13 in cash per fully diluted common share, plus the assumption of $1.5 billion in net debt. The Waltham, MA, laboratory sealed the deal after obtaining regulatory sign-offs from European, Chinese and then U.S. regulators, and had to agree to sell off certain divisions before the Life Tech buyout could be completed. Item

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.